Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) and Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.
Profitability
This table compares Unicycive Therapeutics and Phio Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Unicycive Therapeutics | N/A | -134.69% | -84.51% |
| Phio Pharmaceuticals | N/A | -77.34% | -70.87% |
Earnings and Valuation
This table compares Unicycive Therapeutics and Phio Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Unicycive Therapeutics | $680,000.00 | 217.51 | -$26.56 million | ($2.21) | -2.44 |
| Phio Pharmaceuticals | N/A | N/A | -$8.70 million | ($1.38) | -0.75 |
Phio Pharmaceuticals has lower revenue, but higher earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Unicycive Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Unicycive Therapeutics and Phio Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Unicycive Therapeutics | 2 | 0 | 5 | 0 | 2.43 |
| Phio Pharmaceuticals | 1 | 0 | 1 | 0 | 2.00 |
Unicycive Therapeutics presently has a consensus target price of $21.75, indicating a potential upside of 302.78%. Phio Pharmaceuticals has a consensus target price of $14.00, indicating a potential upside of 1,246.15%. Given Phio Pharmaceuticals’ higher probable upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Unicycive Therapeutics.
Institutional and Insider Ownership
40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Phio Pharmaceuticals beats Unicycive Therapeutics on 7 of the 12 factors compared between the two stocks.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
